Recombinogenic activity of fluoxetine in Aspergillus nidulans.
The recombinogenic potential of fluoxetine, an antidepressant widely prescribed in the treatment of depressive disorders in cancer patients, was investigated in this study. A heterozygous diploid strain of Aspergillus nidulans was utilized. Fluoxetine at 7.5, 15, and 30 microM concentrations induced homozygosity of several nutritional genetic markers and significantly increased their homozygotization index values. Since mitotic recombination is a mechanism leading to malignant growth through the loss of a functional copy of a heterozygous tumor-suppressor gene, fluoxetine may be characterized as an inducer of secondary malignancies in cancer patients after antidepressant treatment.
Departamento de Biologia Celular e Genética, Universidade Estadual de Maringá, Maringá, PR Brazil. maacprado@uem.br
Juliana
J
de Castro-Prado
Claudinéia C da Silva
CC
Franco
Juliane R
JR
de Sant'Anna
Claudia T
CT
Miyamoto
Marialba A A
MA
de Castro-Prado
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000494:pharmacology*; D001233:Aspergillus nidulans / Q000187:drug effects* / Q000235:genetics; D003434:Crossing Over, Genetic; D004171:Diploidy; D004305:Dose-Response Relationship, Drug; D005473:Fluoxetine / Q000009:adverse effects / Q000494:pharmacology*; D005656:Fungal Proteins / Q000235:genetics / Q000378:metabolism; D006579:Heterozygote; D006801:Humans; D019656:Loss of Heterozygosity / Q000187:drug effects* / Q000235:genetics; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects* / Q000502:physiology; D011995:Recombination, Genetic / Q000187:drug effects*
D018687:Antidepressive Agents, Second-Generation; D005656:Fungal Proteins; D005473:Fluoxetine